Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Abpro Holdings ( (ABP) ).
On April 27, 2025, Abpro Holdings, Inc. and Celltrion presented preclinical data for their co-developed ABP-102/CT-P72 at the American Association for Cancer Research Annual Meeting in Chicago. The data showcased the potential of ABP-102/CT-P72 as a best-in-class HER2 x CD3 T-cell engager, highlighting its superior tumor selectivity, efficacy, and safety profile compared to existing therapies. The preclinical findings suggest that ABP-102/CT-P72 could redefine treatment options for HER2-positive cancers by overcoming toxicity barriers and offering a broader therapeutic window, with clinical trials anticipated to begin in 2026.
More about Abpro Holdings
Abpro Holdings, Inc. is a biotechnology company focused on developing next-generation antibody therapies for severe and life-threatening diseases, including HER2+ cancers and other conditions. The company utilizes its proprietary DiversImmune® platform to advance its pipeline of antibody therapies. Abpro is based in Woburn, Massachusetts.
YTD Price Performance: -79.75%
Average Trading Volume: 110,250
Technical Sentiment Signal: Buy
Current Market Cap: $16.61M
For detailed information about ABP stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money